Navigation Links
MDS Nordion Begins to Manufacture Cardiac Imaging Agent

    Bracco's Cardiogen-82(R) Enables Cardiologists to Better Detect
    Cardiovascular Disease

OTTAWA, June 10 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, today announced that it has commenced the manufacture of CardioGen-82(R) (Rubidium-82 generators), for Bracco Diagnostics, Inc. (part of Bracco Group), one of the world's leading companies in the imaging agent business.

MDS Nordion has designed and built a dedicated manufacturing suite within its world-class, U.S. Food and Drug Administration (FDA)-approved, Good Manufacturing Practices (GMP)-compliant production facility in Ottawa. Production of CardioGen-82 began yesterday.

CardioGen-82, the only generator-based, cardiac Positron Emission Tomography (PET) perfusion imaging agent approved by the FDA, produces Rubidium-82, using a specialized generator technology. Once administered to the patient, Rubidium-82 is used as a PET imaging tracer for perfusion studies of the heart to examine blood flow through heart vessels. PET is a highly sensitive medical imaging technique that produces a three-dimensional image of the functioning heart, allowing the cardiologist to identify regions of the heart muscle receiving poor blood flow.

"There is growing interest in advanced molecular imaging technologies to help better diagnose and treat disease," said Steve West, President of MDS Nordion. "MDS Nordion provides a full spectrum of services for the development and commercialization of novel radiopharmaceuticals. For more than 10 years, companies like Bracco have been relying on our proven track record for innovative solutions, quality, and reliability that make MDS Nordion the partner of choice."

A 2007 Frost & Sullivan report entitled U.S. PET and PET-CT (Computerized Tomography) Imaging Equipment Markets indicated that use of PET imaging as a diagnostic tool is on the rise. For the period 2007-2014, the report projects a total compounded annual growth rate of 17.3% for PET and PET-CT.

"This is an important milestone in the development of Bracco's innovative cardiac imaging technology and the new MDS facility provides Bracco with a world-class manufacturing capability with significant capacity for future expansion to meet anticipated market growth," said Carlo Medici, President and Chief Executive Officer of Bracco Diagnostics, Inc. "MDS Nordion's unique expertise in the development and manufacture of radiopharmaceuticals, along with its highly specialized facilities, made them an obvious choice when Bracco looked to expand its CardioGen-82 production capacity."

MDS Nordion offers tailored solutions, leading expertise and service capabilities for radiopharmaceutical development, clinical and commercial manufacturing, and radiation-based medical device development. MDS Nordion has GMP-compliant facilities in Ottawa and Vancouver, Canada, and Fleurus, Belgium that can accommodate a variety of development, manufacturing, and supply requirements.

About Bracco Imaging S.p.A.

Bracco Imaging S.p.A. is one of the world's leading companies in the diagnostic imaging business. Bracco Imaging develops, manufactures, and markets diagnostic imaging agents and solutions that meet medical needs and facilitate clinical solutions. Headquartered in Milan, Italy, Bracco Imaging operates in over 80 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses, and distribution partnership agreements.

Bracco Imaging is a subsidiary of Bracco S.p.A., the holding company of the Bracco Group which also markets ethical and over-the-counter (OTC) pharmaceutical products in Italy as well as advanced medical technology systems worldwide. Furthermore, the Bracco Group offers diagnosis services through the Milan-based Centro Diagnostico Italiano (Italian Diagnostic Center). For more information, visit

About MDS Nordion

MDS Nordion, a business unit of MDS Inc., is a global leader in providing medical isotopes for molecular and diagnostic imaging, radiotherapeutics, and sterilization technologies for medical products that benefit the lives of millions of people in more than 50 countries around the world. MDS Nordion products and services are used on a daily basis by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics, and research laboratories. Find out more at

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at or by calling 1-888-MDS-7222, 24 hours a day.

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage
2. MDS Nordion Opens New Radiopharmaceutical Production Facility in Belgium
3. MDS Nordion Provides Update on AECLs Medical Isotope Supply Disruption
4. MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians
5. Dr. Peter Covitz Joins MDS Nordion as Senior Vice-President Innovation
6. MDS Nordion Provides Update to Medical Isotope Customers
7. MDS Nordion Divests Non Strategic Product Lines
8. MDS Nordion signs 17-year contract with Rosenergoatom
9. Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)
10. Thomas R. Frieden, M.D., M.P.H., Begins Role as CDC Director and ATSDR Administrator
11. NTS Begins Testing for ZigBee RF4CE Specification
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... leading provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today ... Partner Program with competencies in the Application Development, demonstrating a “best-in-class” ability ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant coding-related changes are ... likely to include new codes for spine and hip X-rays, paravertebral facet blocks ... of code changes in musculoskeletal, radiology and nervous system sections on an Orthopedic ...
(Date:11/29/2015)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... Women's Excellence is once again accredited by the American Institute of Ultrasound ... process that allows practices to demonstrate that they meet or exceed nationally ...
(Date:11/29/2015)... ... November 29, 2015 , ... While conventional walkers afford considerable ... ready access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has found a ... to enhance the benefits of a standard walker to improve the user’s quality of ...
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad , a ... Chris Hafey and Claude Hooton to its board of directors. The announcement comes ... (RSNA) 2015 Annual Meeting and continues to strategically transform its focus from being ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , November 30, 2015 ... directed at up to 10 G protein-coupled receptor (GPCR) ... ) to research and develop potential new medicines directed ... across multiple therapeutic areas. --> Heptares Therapeutics ... company and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . ... --> Pharmaboardroom releases its new 98-page Mexico Healthcare and ... , a country of over 122 million people. --> ... people. --> It offers companies, investors, policymakers, and stakeholders ... the second largest pharma and healthcare market in Latin ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. ... pharmaceutical company focused on acquiring and developing innovative therapies ... the appointment of Keith A. Katkin as ... Gregory J. Flesher , chief executive officer for OticPharma, ... successful organizations.  As chairman, he will be able to ...
Breaking Medicine Technology: